REQUEST A DEMO
Total
USD $0.00
Search more companies

Donga Pharmaceutical Co.,Ltd. (South Korea)

Main Activities: Pharmaceutical and Medicine Manufacturing | Medicinal and Botanical Manufacturing
Full name: Donga Pharmaceutical Co.,Ltd. Profile Updated: December 09, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

Donga Pharmaceutical Co.,Ltd. is a company based in South Korea, with its head office in Seoul. It operates in the Pharmaceutical and Medicine Manufacturing industry. The company was established on March 01, 2013. The total number of employees is currently 981 (2024). In 2023, the company reported a net sales revenue increase of 16.21%. Its’ total assets recorded a growth of 5.58%. The enterprise’s net profit margin increased by 0.38% in 2023.

Headquarters
64, Cheonho-daero Dongdaemun-gu Seoul
Seoul; Seoul;

Contact Details: Purchase the Donga Pharmaceutical Co.,Ltd. report to view the information.

Website: http://www.dapharm.com

Basic Information
Total Employees:
Purchase the Donga Pharmaceutical Co.,Ltd. report to view the information.
Outstanding Shares:
Purchase the Donga Pharmaceutical Co.,Ltd. report to view the information.
Registered Capital:
Purchase the Donga Pharmaceutical Co.,Ltd. report to view the information.
Incorporation Date:
March 01, 2013
Key Executives
Purchase this report to view the information.
Chairman
Ownership Details
Purchase this report to view the information.
100%
Subsidiaries
Dong-A Socio Holdings Co.,Ltd.
Company Performance
Financial values in the chart are available after Donga Pharmaceutical Co.,Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
16.21%
Total operating revenue
16.21%
Operating profit (EBIT)
18.55%
EBITDA
15.26%
Net Profit (Loss) for the Period
20.74%
Total assets
5.58%
Total equity
9.63%
Operating Profit Margin (ROS)
0.25%
Net Profit Margin
0.38%
Return on Equity (ROE)
3.15%
Debt to Equity Ratio
2.83%
Quick Ratio
0.03%
Cash Ratio
-0.07%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?